Vaxart, Inc. Available-for-sale Securities, Short-term Investments, Amortized Cost (Deprecated 2018-01-31)
Vaxart, Inc. (VXRT) had Available-for-sale Securities, Short-term Investments, Amortized Cost (Deprecated 2018-01-31) of $27.10 million as of 2015-09-30, per its 10-Q filed 2015-11-06.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesShortTermInvestmentsAmortizedCost · last filed 2015-11-06
- 2015-09-30: Available-for-sale Securities, Short-term Investments, Amortized Cost (Deprecated 2018-01-31) $27.10M.
- 2015-06-30: Available-for-sale Securities, Short-term Investments, Amortized Cost (Deprecated 2018-01-31) $27.20M.
- 2015-03-31: Available-for-sale Securities, Short-term Investments, Amortized Cost (Deprecated 2018-01-31) $34.20M.
- 2014-12-31: Available-for-sale Securities, Short-term Investments, Amortized Cost (Deprecated 2018-01-31) $39.90M.
| Period end | Available-for-sale Securities, Short-term Investments, Amortized Cost (Deprecated 2018-01-31) |
|---|---|
| 2015-09-30 | $27.10M 10-Q · filed 2015-11-06 |
| 2015-06-30 | $27.20M 10-Q · filed 2015-11-06 |
| 2015-03-31 | $34.20M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $39.90M 10-Q · filed 2015-02-06 |
| 2014-09-30 | $43.30M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $46.90M 10-K · filed 2015-09-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |